Biogen, Eisai Report BAN2401 Seemingly Positive In Alzheimer's; Others Skeptical
Executive Summary
Further new data for the Biogen and Eisai drug BAN2401 appear to show it significantly reduces amyloid plaque and cognitive declines in Alzheimer's patients in a dose-dependent manner, but a lot of questions – and skepticism about the data – remain.
You may also be interested in...
Eisai’s Lecanemab BLA Filing A Key Step For Ailing Biogen
Aduhelm commercialization was a bust, so Biogen’s next big hope for a potential blockbuster Alzheimer’s therapy is partner Eisai’s amyloid protofibril-targeting antibody lecanemab.
Looking Past Aduhelm, Biogen Puts Pipeline On Display
In an attempt to show Biogen has more than its troubled Alzheimer’s drug Aduhelm to drive revenue growth, the company’s R&D Day highlighted several programs from its portfolio of 33 clinical-stage assets.
BACE Hopes Finally Fizzle As Biogen/Eisai End Elenbecestat Alzheimer's Studies
Biogen investors cheered the end of the company’s investment in the Phase III studies due to an unfavorable risk-benefit ratio – a widely expected result for the last clinical BACE inhibitor program.